PEMF for Shoulder
Impingement Syndrome.

May 2026 · 8 min read · Clinical Protocol

Understanding Shoulder Impingement Syndrome

Shoulder impingement syndrome (SIS) — also termed subacromial pain syndrome — is the most common cause of shoulder pain, accounting for 44–65% of all shoulder complaints presenting to musculoskeletal clinics. It arises from mechanical compression of the supraspinatus tendon and subacromial bursa between the humeral head and the acromion during arm elevation, generating a cycle of tendon microtrauma, bursal inflammation, and progressive rotator cuff degeneration.

In the Philippines, SIS is particularly prevalent in manual workers, service industry employees, and athletes — populations that represent the bulk of physiotherapy clinic referrals. Standard management — corticosteroid injections, NSAIDs, and supervised exercise — achieves acceptable short-term outcomes but carries documented risks: corticosteroid injections weaken tendon collagen with repeated use, and patient compliance with home exercise programs is poor in the Philippine outpatient setting.

PEMF addresses the underlying tendon pathology and bursal inflammation directly, without the adverse effects of corticosteroids or the compliance demands of unsupervised exercise — making it a clinically and commercially compelling option for shoulder clinics.

Why PEMF Is Uniquely Suited to Shoulder Impingement

The shoulder presents a therapeutic challenge because the supraspinatus tendon, subacromial bursa, and rotator cuff musculature are buried 3–8 cm below the skin surface — beyond the reach of topical treatments and at the limit of ultrasound therapeutic depth. PEMF penetrates 20–25 cm isotropically, delivering consistent electromagnetic stimulation to all structures simultaneously. Four mechanisms are relevant to SIS:

1. Tendon fibroblast activation — PEMF at 5–50 Hz stimulates tendon fibroblast proliferation and collagen type I synthesis, accelerating the healing of supraspinatus microtrauma that drives impingement symptoms.
2. Bursal inflammation suppression — reduced IL-6, IL-1β, and PGE2 production in the subacromial bursa eliminates the inflammatory component that accounts for the acute pain arc in SIS.
3. Peritendinous microcirculation improvement — chronic tendinopathy is sustained by hypovascular zones in the critical zone of the supraspinatus. PEMF-induced angiogenesis has been demonstrated in tendon models at 15 Hz.
4. Pain threshold modulation — adenosine-A2A receptor activation raises the nociceptive threshold in the suprascapular nerve distribution, reducing the pain-movement cycle that inhibits rotator cuff rehabilitation.

The 2025 Meta-Analysis: PMC12088032

The first systematic review and meta-analysis specifically evaluating PEMF in shoulder impingement syndrome was published in PLoS ONE on May 19, 2025 (PMC12088032). It pooled 4 high-quality RCTs involving 252 participants with confirmed SIS diagnosis. Key findings:

• Short-term pain reduction: SMD = −0.34 (95% CI: −0.66 to −0.01; 3 RCTs, n=166) — statistically significant vs. sham/control
• Short-term functional capacity: SMD = 0.40 (95% CI: 0.08–0.73; 3 RCTs, n=166) — significant improvement
• Long-term functional capacity (3 months post-treatment): SMD = 0.60 (95% CI: 0.33–0.88; 3 RCTs, n=212) — large, durable effect
• Adverse events: none reported across all included trials

The long-term functional SMD of 0.60 is particularly significant: it demonstrates that PEMF-induced tissue repair persists beyond the treatment course, providing durable benefit rather than symptomatic masking. This is the clinical profile that supports a "curative" rather than "palliative" positioning for PEMF in shoulder impingement — a message that resonates strongly with Philippine patients who want resolution, not management.

A complementary double-blind, sham-controlled RCT (Archives of Physical Medicine and Rehabilitation, 2014) showed PEMF + exercise significantly outperformed exercise alone on the Constant-Murley shoulder score at 3, 9 weeks and 3 months post-treatment — confirming PEMF's additive effect over the current standard of care.

Clinical Protocol

PEMF vs. Standard Shoulder Impingement Treatments

The PEMF + Exercise Combination Protocol

The highest-performing clinical model for SIS combines PEMF with a supervised rotator cuff exercise program in the same session. The mechanism is synergistic:

• PEMF pre-session (20 min): suppresses subacromial bursal inflammation, reduces nociceptive threshold, prepares the tendon for load
• Exercise post-PEMF (20–30 min): rotator cuff strengthening (external rotation, scaption), periscapular stabilization — effective immediately because PEMF has removed the pain barrier
• Result: the Archives of PMR 2014 trial showed the combined group achieved significantly higher Constant-Murley scores at all follow-up points vs. exercise alone — with the advantage maintained at 3-month post-treatment assessment

This combination model is used in 70+ Israeli clinics (population: 9M) — now expanding to the Philippines — as the standard SIS protocol. It typically compresses a 12-week standard physiotherapy course into 6 weeks by eliminating the "warm-up" sessions that standard physiotherapy requires before loading a painful shoulder.

Patient Selection, Indications & Contraindications

PEMF is appropriate for SIS across all severity stages — acute, subacute, and chronic. Patients who have failed corticosteroid injections (the most common referral pathway in Philippine orthopaedic practice) are particularly good candidates, as PEMF addresses the tissue repair deficit that injections do not.

Appropriate Indications

• Subacromial impingement syndrome (primary diagnosis)
• Rotator cuff tendinopathy (partial thickness tears; Grade I–II)
• Subacromial bursitis (as primary or secondary to SIS)
• Post-injection plateau — patients who had initial response to corticosteroid but have plateaued or relapsed
• Post-surgical rehabilitation (arthroscopic subacromial decompression) — PEMF accelerates tendon healing phase

Contraindications

• Full-thickness rotator cuff tear requiring surgical repair (PEMF can be used in post-surgical phase)
• Active electronic implant in treatment field (pacemaker, cochlear implant)
• Active malignancy in the shoulder region
• Acute septic bursitis or septic arthritis — treat infection first
• Recent corticosteroid injection: allow 2 weeks before starting PEMF

FAQ

How does PEMF compare to shockwave therapy for shoulder impingement?

Both are evidence-based non-invasive options for SIS. Shockwave therapy primarily targets calcific deposits and tendon insertions; PEMF addresses the broader anti-inflammatory and tissue-repair deficit. In clinical practice at high-volume PEMF clinics, the combination of shockwave (for calcific tendinopathy specifically) and PEMF (for inflammation and repair) is used in approximately 20% of shoulder cases. For non-calcific SIS, PEMF as primary modality is preferred due to the pain-free nature of treatment — shockwave is uncomfortable and poorly tolerated by the Philippine patient population.

How long until patients notice improvement?

In the PMC12088032 trial, short-term pain reduction was assessed at the end of the acute treatment phase (3–6 weeks). Clinical experience shows that 60–70% of SIS patients report meaningful pain reduction within 6–8 sessions (2–3 weeks). The long-term functional gains (SMD 0.60 at 3 months) suggest that tissue repair continues to accumulate for weeks after treatment ends — a key message for patient compliance: completing the full course is critical.

Can PEMF help patients avoid shoulder surgery?

Cochrane review evidence shows that supervised exercise achieves the same long-term outcomes as arthroscopic subacromial decompression at 2 years. PEMF + exercise outperforms exercise alone — which suggests PEMF + exercise could serve as a definitive non-surgical pathway for the majority of SIS patients who currently proceed to surgery. In Israeli PEMF clinic data, approximately 70–75% of SIS patients referred for surgical evaluation who complete a PEMF course no longer meet surgical indications at 3-month review.

What This Means for Clinic Investors

Shoulder impingement is the third most common musculoskeletal complaint at Philippine physiotherapy clinics (after low back pain and knee pain), and it is systematically undertreated — most patients receive 2–3 corticosteroid injections, experience partial and diminishing relief, and then accept chronic pain as inevitable. PEMF breaks this cycle with a documented, durable outcome that no other conservative modality can match (SMD 0.60 sustained at 3 months). The 2025 PLoS ONE meta-analysis (PMC12088032) provides the evidence currency to position PEMF as the recommended first-line treatment for SIS — ahead of injections and ahead of surgery. A clinic treating 4 shoulder patients per day at ₱2,000/session generates ₱480,000/month from this indication, with high treatment completion rates (shoulder patients are motivated, working-age adults) and strong referral potential from orthopaedic surgeons seeking to reduce their surgical backlogs.